References
- Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. Health Qual Life Outcomes 2006;4:62
- Yost KJ, Sorensen MV, Hahn EA, et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005;8:117-27
- Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labeling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006;4:69
- Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70
- Jaeschke R, Singer J, Guyatt GH. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15
- Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14:285-95
- Sloan JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. Int J Chron Obstruct Pulmon Dis 2005;2:57-62
- US FDAGuidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79
- Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9
- McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-14
- Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 2008;24:2767-76
- George JN. Diagnosis, clinical course, and management of idiopathic thrombocytopenic purpura. Curr Opin Hematol 1996;3:335-40
- McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with immune thrombocytopenic purpura. Am J Hematol 2008;83:150-4
- Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11
- Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-62
- Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
- Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988
- Khanna D, Furst DE, Wong W, et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2006;16:1083-92
- Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004;57:1153-60
- Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific questionnaire. J Clin Epidemiol 1994;47:81-7
- Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York, NY: McGraw-Hill, 1994